Background: Mounting evidence has displayed critical roles of circular RNAs (circRNAs) in multiple cancers. The underlying mechanisms by which circFGD4 contributed to gastric cancer (GC) are still unclear. Methods: The levels and clinical values of circFGD4 in GC patients were detected and analysed by quantitative real-time PCR. The biological roles of circFGD4 in GC were assessed in vitro and in vivo experiments. Dual-luciferase reporter, fluorescence in situ hybridization, RNA immunoprecipitation, biotin-coupled RNA pull-down, and TOP/Flash and FOP/Flash reporter gene assays were employed to evaluate the effects of circFGD4 on miR-532-3p-mediated adenomatous polyposis coli (APC)/β-catenin signalling in GC cells. Results: circFGD4 expression was down-regulated the most in human GC tissues and cell lines. Low expression of circFGD4 was correlated with poor tumour differentiation, lymphatic metastasis, and poor prognosis of GC patients. circFGD4 suppressed GC cell viability, colony formation, migration, induced epithelial–mesenchymal transition (EMT), and tumorigenesis and metastasis in vivo. Next, we validated that circFGD4 acted as a sponge of miR-532-3p to relieve the tumour-promoting effects of miR-532-3p on its target APC. The mechanistic analysis demonstrated that the circFGD4 suppressed GC cell viability, migration, and EMT by modulating the miR-532-3p/APC axis to inactivate the β-catenin signalling. Conclusion: circFGD4 suppressed GC progression through sponging miR-532-3p and enhancing APC expression to inactivate the β-catenin signalling. Thus circFGD4 provides a novel potential biomarker and valuable therapeutic strategy for GC.
Background: Mounting evidence exhibits circRNAs as critical regulators in the progression of many tumors. The regulatory function and potential mechanism by which circ_0008126 in gastric cancer (GC) is unknown. Methods: To validate and analyze the expression levels and clinical values of circ_0008126 in GC patients, the biological phenotypes of circ_0008126 in GC were investigated in vitro and in vivo. The roles and effects of circ_0008126 on miR-502-5p, EIF4A3, and APC in GC cells were explored using rescue experiment, RNA stability assay, RNA pull-down, dual-luciferase reporter, RNA immunoprecipitation (RIP), RNA FISH, immunofluorescence (IF), and TOP/Flash and FOP/Flash assays. Results: Circ_0008126 expression levels were prominently down-regulated in GC tissues and cells. Importantly, low expression of circ_0008126 was relevant to the more lymphatic metastasis, advanced TNM stage, and poor survival period in patients with GC. Functionally, circ_0008126 inhibited GC cell proliferative activity, metastatic ability, and epithelial-mesenchymal transition (EMT) in vitro and vivo. Mechanistically, we verified that EIF4A3 can mediate the formation of circ_0008126, and circ_0008126 could competitively bind miR-502-5p and alleviate its role and effect on APC, thus inactivating the β-catenin pathway in GC. Additionally, circ_0008126 was determined to increase the stability of APC mRNA by interacting with cytoplasmic EIF4A3 protein and then enhancing the APC expression. Conclusions: These data demonstrate that EIF4A3-mediated circ_0008126 could regulate the APC expression and inactivate the β-catenin pathway partly by binding to miR-502-5p and EIF4A3, thus inhibiting the tumorigenesis and development of GC.
Chemokines have been reported to be involved in tumorigenesis and progression and can also modulate the tumor microenvironment. However, it is still unclear whether chemokine-related long noncoding RNAs (lncRNAs) can affect the prognosis of colon adenocarcinoma (COAD). We summarized chemokine-related genes and downloaded RNA-seq and clinical data from The Cancer Genome Atlas (TCGA) database. A total of 52 prognostic chemokine-related lncRNAs were screened by univariate Cox regression analysis; patients were grouped according to cluster analysis results. Lasso regression analysis was applied to determine chemokine-related lncRNAs to construct a risk model for further research. This study first investigated the differences between the prognosis and immune status of two chemokine-related lncRNAs clusters by consensus clustering. Then, using various algorithms, we obtained ten chemokine-related lncRNAs to construct a new prognostic chemokine-related lncRNAs risk model. The risk model’s predictive efficiency, validity, and accuracy were further validated and determined in the test and training cohorts. Furthermore, this risk model played a vital role in predicting immune cell infiltration, immune checkpoint gene expression, tumor mutational burden (TMB), immunotherapy score, and drug sensitivity in COAD patients. These findings elucidated the critical role of novel prognostic chemokine-related lncRNAs in prognosis, immune landscape, and drug therapy, thereby providing valuable insights for prognosis assessment and personalized treatment strategies for COAD patients.
Resistance to anti-PD-1 immunotherapy remains a critical challenge in colorectal cancer (CRC). However, the functional role of S100A14 in CRC remains controversial regarding its oncogenic status and impact on immunotherapy response. Here, integrating single-cell RNA sequencing and tissue microarray analysis, we definitively identify S100A14 as an oncogenic driver of immunotherapy resistance. High S100A14 expression correlates with poor prognosis and an immunosuppressive “cold” tumor phenotype. Mechanistically, S100A14 directly binds UPF1, a core nonsense-mediated mRNA decay (NMD) factor, promoting its ubiquitination-mediated degradation. This impairs the decay of non-canonical NF-κB transcripts (MAP3K14, NFKB2, RELB), causing constitutive pathway activation and PD-L1 upregulation. In co-culture assays, S100A14-overexpressing cells directly suppressed CD8 + T-cell cytotoxicity by downregulating GZMB and induced exhaustion via PD-1 upregulation. In syngeneic mouse models, S100A14 overexpression accelerated hepatic metastasis and conferred anti-PD-1 resistance by suppressing GZMB + CD8 + T-cell infiltration and promoting Treg recruitment. Notably, restoring UPF1 expression reversed malignant phenotypes in vitro and rescued S100A14-mediated immune evasion in co-culture models. Collectively, we define the S100A14-UPF1-non-canonical NF-κB axis as a actionable mechanism driving immune evasion in CRC.
Background To elucidate the prognostic patterns of m6A-related lncRNAs and construct a prognostic model of m6A-related lncRNAs in Kidney renal papillary cell carcinoma (KIRP). Methods We downloaded KIRP-related RNA-seq and clinical data from the TCGA dataset. Potential m6A-related prognostic lncRNAs in KIRP patients were selected by Pearson correlation test and univariate Cox analysis. KIRP patients were divided into two clusters using consensus clustering. The prognostic model of m6A-related lncRNAs was constructed to explore the relationship between m6A-related lncRNAs and clinical features and survival data using LASSO regression analysis. We also determined the relationship of risk models to tumor microenvironment (TME) and drug sensitivity. Results We first identified two m6A-related lncRNA pattern clusters by consensus clustering based on 32 m6A-related prognostic lncRNAs. Patients from cluster 2 were dramatically associated with poor prognosis, worse clinical grades, etc. Cluster 2 not only had higher immuneScore, ESTIMATEScore, and stromalScore but was also associated with higher levels of immune cell infiltration and expression of immune checkpoint molecules. Then, 14 m6A-related prognostic lncRNAs were selected and validated as independent and robust predictors of KIRP prognosis. Two nomograms based on age, tumor grade, clinical stage, and m6A-related lncRNAs expression were generated, showing high accuracy and reliability in predicting overall survival in KIRP patients. KIRP patients in the high-risk group had higher pN stage, pT stage, pM stage, advanced clinical stage, and higher tumor grade than the low-risk group. Importantly, cluster 2 with worse overall survival had a higher risk score than cluster 1, thus indicating consistency between the two methods for predicting survival in KIRP. Furthermore, some tumor-infiltrating immune cells, immune checkpoint molecules, and drugs sensitivity were closely related to the risk score of the prognostic model in KIRP patients. Conclusion We not only established a model of novel m6A-related prognostic lncRNAs with favorable prognostic value in KIRP patients, but also could provide new insights into tumorigenesis and predict treatment response in KIRP patients.